Medline ® Abstract for Reference 83
of 'Induction therapy for acute myeloid leukemia in younger adults'
Long-term remission in BCR/ABL-positive AML-M6 patient treated with Imatinib Mesylate.
Pompetti F, Spadano A, Sau A, Mennucci A, Russo R, Catinella V, Franchi PG, Calabrese G, Palka G, Fioritoni G, Iacone A
Leuk Res. 2007;31(4):563. Epub 2006 Aug 17.
BCR/ABL-positive acute myeloid leukemia (AML) is a rare disease, characterized by a poor prognosis, with resistance to induction chemotherapy and frequent relapses in responsive patients. Here we report a case of BCR/ABL-positive AML-M6 who, after relapse, was treated with Imatinib Mesylate (600 mg/die) and within 4 months achieved a cytogenetic and molecular complete response. After more than 4 years of continuous Imatinib therapy, nested RT-PCR for BCR/ABL is persistently negative. The case reported shows that the response obtained with Imatinib Mesylate in BCR/ABL-positive AML may be long lasting, offering a chance of successful treatment for this poor prognosis group of patients.
Molecular Biology Laboratory, Department of Transfusional Medicine, Ospedale Civile Spirito Santo, Pescara-Italy.